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Background: Residual neuro-muscular blockade after the end of general anaesthesia may occur when non-depolarising muscle 
relaxant (NDMR) drugs are used. Train-of-four (TOF) stimulation is used to quantify the degree of residual paralysis, with a TOF 
ratio of less than 0.9 postoperatively associated with increased morbidity in patients. The aim of this study was to survey the 
degree of residual paralysis in patients in the post-anaesthesia care unit (PACU) at Inkosi Albert Luthuli Central Hospital (IALCH), 
Durban, over the survey period.
Methods: This cross-sectional observational study was performed over a two-month period at IALCH, assessing the postoperative 
neuromuscular function of patients who had received NDMR drugs (rocuronium (n = 64) or cisatracurium (n = 6)) intraoperatively. 
Muscle function was assessed using acceleromyography and TOF stimulation, utilising a TOF Watch SX device, with function 
grouped according to previously defined targets as less than a ratio of 0.7, less than a ratio of 0.9 and less than a ratio of 1.0.
Results: Recovery to a TOF ratio of less than 0.7, 0.9 or 1.0 was observed in 5 (7.1%), 20 (28.6%) and 44 (62.9%) of patients 
respectively.
Conclusions: Although the results obtained compare favourably with other studies in similar patient populations, a considerable 
subset of patients still arrive in the PACU with inadequate return of neuromuscular function.
Keywords: post-anaesthesia, postoperative residual curarisation, postoperative residual weakness, residual block, residual 
neuromuscular block, residual paralysis
Introduction
Since the 1940s, muscle relaxants have formed an essential 
component of general anaesthesia, greatly improving surgical 
conditions.1 Associated with the use of these drugs, however, are 
multiple risks including the risk of incomplete reversal of 
neuromuscular blockade at the end of surgery. Already as early as 
1954 a sixfold increase in mortality was being reported in patients 
who had received muscular paralysis as part of their anaesthetic.2
Clinical measures to assess neuromuscular function have long 
been used in anaesthesia and include amongst others, the five-
second head-lift, tongue protrusion, jaw clench, grip strength 
and assessment of tidal volume.3–5 Studies soon showed, 
however, that despite the ability to perform these clinical tests, 
significant impairment in muscle function could still persist.3,4,6 
Recent studies have shown clinical measures to be both 
unreliable and insensitive; however, despite this, many 
anaesthetists persist in relying on these tests as the sole 
indicators of recovery from neuromuscular blockade.7, 8
Using evoked responses as a measure of muscle function was 
popularised after the development of the train-of-four (TOF) 
method of neurostimulation in the 1970s.9 A TOF refers to four 
supramaximal impulses delivered at 0.5 second intervals which 
in turn result in four measurable muscle twitches. These twitches 
can then be assessed either subjectively using visual or tactile 
methods of assessment, or objectively using various devices. The 
advantage of the TOF lies in the fact that, as a ratio, baseline 
measurement of muscular function is not needed in order to 
interpret the result.10
Visual or tactile assessments utilising peripheral nerve 
stimulation, while often better than clinical methods, still exhibit 
poor sensitivity for detecting clinically significant levels of 
residual neuromuscular blockade, with most evaluators unable 
to discriminate past a TOF ratio of 0.4.8 This poor sensitivity is 
exacerbated when assessed by junior or relatively inexperienced 
anaesthetists.11 Objective quantitative measures of 
neuromuscular function have subsequently been developed. 
These include mechanomyography, which utilises a strain gauge 
to measure muscular tension; electromyography, which utilises 
electrodes to measure the compound muscle potential; 
kinemyography, based on the piezoelectric effect caused by the 
deformation of a mechanosensor; phonomyography, which 
measures the low-frequency sounds created by muscle 
contraction; and acceleromyography, which also utilises a 
piezoelectric sensor, but this time to measure acceleration 
produced by the muscle twitch which in turn is directly 
proportional to the force of muscle contraction.12,13 
Mechanomyography is still considered the gold-standard 
measurement technique; however, it is complicated and bulky to 
set up and use in daily practice.14
Quantitative neuromuscular monitoring has become widely 
available in many centres, with acceleromyography favoured 
over alternative methods due to its reproducibility, sensitivity 
and ease of use in a clinical context.8 Several studies have shown 
the benefit of intraoperative use of acceleromyography in 
significantly reducing the incidence of postoperative residual 
curarisation but, despite this, it is still often not routinely applied 
in the clinical setting.15–17
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It has long been recognised that residual neuromuscular blockade 
may adversely affect the patient’s outcomes in the postoperative 
period.18 Various studies have measured both the physiological 
and clinical sequelae of postoperative residual curarisation, and 
these findings have been incorporated into recommended 
anaesthetic practice over the years.2,10,19–23 With the advent of 
neuromuscular monitors and the increased use of TOF monitoring 
to assess degree of neuromuscular blockade, a TOF ratio greater 
than 0.7 was recommended in order to minimise postoperative 
morbidity and mortality associated with the use of NDMR drugs.9 
This number was based on the studies of Ali et al. published in 
1975, who correlated TOF ratios to measurements of respiratory 
reserve, namely, vital capacity, negative inspiratory force and peak 
expiratory flow rate.18 More recently, in the mid-1990s it began to 
emerge that even relatively high levels of motor recovery (TOF 
0.7–0.9) were still associated with significant negative objective 
outcomes such as impaired inspiratory function, decreased 
hypoxic drive, increased incidence of bronchial obstruction, 
decreased oesophageal sphincter tone, functional impairment of 
pharyngeal muscles, increased episodes of aspirations and 
delayed discharge from the recovery room.8,10,24–26 Furthermore, 
TOF ratios of less than 0.9 are strongly associated with unpleasant 
subjective experiences for the patient including diplopia, difficulty 
speaking, difficulty swallowing, unsteady gait and sensations of 
fatigue and muscle weakness.8,10,24–26 These newer studies have 
resulted in a recovery to a TOF of 0.9 or greater prior to extubation 
becoming widely adopted as a standard of anaesthetic practice 
following non-depolarising neuromuscular blockade.5,10,21,27 
Furthermore, recent studies have illustrated a small degree of 
overestimation of the TOF ratio when utilising acceleromyography. 
This has raised the possibility that in clinical practice TOF ratios of 
1.0 should be targeted to ensure an effective TOF ratio greater 
than 0.9 when utilising acceleromyographic-based monitoring 
equipment such as the TOF-Watch®.28,29
The reported incidence of postoperative residual curarisation 
varies widely with published studies reporting an incidence as 
low as 3% in some centres,30 while other studies have reported 
incidences as high as 88% in other centres.3,31 This large variance 
may be partly due to the differing methodology applied by the 
studies, as well as different criteria used to define postoperative 
residual curarisation. A recent meta-analysis estimates that 
around 40% of patients arrive in the post-anaesthesia care unit 
postoperatively with a TOF of less than 0.9, and around 12% with 
a TOF of less than 0.7.27
Unfortunately there is little information available regarding the 
incidence of residual neuromuscular blockade following surgery 
in the South African context. A study of 70 patients at Universitas 
Hospital in Bloemfontein published in 2004 reported only 57.1% 
of their subjects recovering to a TOF > 0.9, suggesting the 
possibility that other hospitals in South Africa may also 
demonstrate a similar poor level of postoperative muscular 
recovery in their patients too.22 Importantly, however, since then 
the routine non-depolarising muscle relaxant drugs used have 
changed with the widespread adoption of rocuronium into daily 
practice, as well as the decrease in the use of older drugs such as 
vecuronium and atracurium. This emphasises the need for 
further studies to help clarify the current extent of the problem 
in the South African context.
Methodology
Overview
The study is designed as a prospective non-randomised cross-
sectional study of the degree of neuromuscular function of 
eligible patients, as defined by a TOF ratio, presenting at Inkosi 
Albert Luthuli Central Hospital over a defined two-month period, 
November 1, 2015 to December 31, 2015. Ethical approval to 
conduct the study was granted by the Biomedical Research 
Ethics Administration of the University of KwaZulu-Natal 
(Reference: BE057/14).
Population and study sample
The population from which the sample was drawn were patients 
who had recently arrived in the PACU (within 15 minutes of 
arrival), and had received intraoperative non-depolarising 
neuromuscular blocking agents. The anaesthetist was not 
notified that testing of neuromuscular function was to be 
performed in the PACU. Only patients who had been extubated 
were included in the study. Furthermore the study included only 
patients who had given prior informed consent. A convenience 
sampling strategy was utilised.
Technical information
Upon arrival at the PACU, eligible patients were evaluated within 
15 minutes using a TOF-Watch SX® accelerometer-equipped 
neurostimulator (Schering-Plough Corp, Kenilworth, NJ, USA). 
The device was applied according to manufacturer 
recommendations. The ulnar nerve was stimulated with TOF 
stimulation (4 pulses 0.2 ms in duration, at a frequency of 2 Hz), 
with a supra-maximal stimulation being applied. Subsequent 
muscle twitches from the adductor pollicis were recorded. 
Results were recorded as a TOF value between 0 and 1 as 
displayed on the device. Data were collected by the principal 
researcher and stored on a password-protected Excel® (Microsoft 
Corp, Redmond, WA, USA) spreadsheet file.
Statistics
Data were grouped into three groups. The first group included all 
patients with a TOF ratio less than 1. The second group, a subset 
of the first, included all patients with a TOF ratio less than 0.9. The 
final group, a subset of the second, included all patients with a 
TOF ratio less than 0.7. Data were entered into SPSS® version 21 
(Statistical Packages for the Social Sciences; IBM Corp, Armonk, 
NY, USA) for analysis. A p-value  <  0.05 was considered as 
statistically significant. A descriptive statistical analysis of the 
data (means, standard deviations, ranges, frequencies and 
percentages, etc.) was initially conducted prior to conducting 
Fisher’s exact test to test any associations between categorical 
variables.
Results
A total of 70 patients met the inclusion criteria and were 
evaluated. Among the 70 patients, 44 (62.9%) had a TOF ratio less 
than 1.0, 20 (28.6%) had a TOF ratio less than 0.9, and 5 (7.1%) 
had a TOF ratio less than 0.7, within 15 minutes of arrival at the 
PACU. The mean TOF ratio measured was 0.91  +  –0.12 (95% CI 
0.88; 0.94).
Thirty-eight (54.3%) of the patients were male and 32 (45.7%) 
were female. The TOF ratio differences between male and females 
were not significant for the less than 0.7 (p = 1.00), less than 0.9 (p 
= 0.940) or less than 1.0 (p = 0.423) cut-offs. The patients’ ages 
ranged from 13 to 86 years old, with a mean age of 46.76 years; 7 
(10%) of patients were greater or equal to 65  years old. The 
difference between TOF ratios between patients older than or 
equal to, or those younger than 65 years old was not significant 
for either the less than 0.7 (p = 0.419), less than 0.9 (p = 1.00) or 
less than 1.0 (p = 1.00) cut-offs.
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Three patients did not receive neostigmine as a reversal agent for 
their non-depolarising muscle block. Of these, one patient had a 
TOF ratio less than 1.0, and none had a TOF ratio less than 0.9.
More patients recovered to a TOF ratio of less than 0.9 that had 
received rocuronium than had received cisatracurium although 
this result was not statistically significant (Fisher’s exact test, p = 
0.051) (see Table I). There was no statistically significant difference 
between rocuronium and cisatracurium when using a TOF ratio 
of 0.7 as a cut-off (Fisher’s exact test, p = 0.37) (see Figure 1).
Discussion
Non-depolarising muscle relaxants are an indispensable part of 
general anaesthesia. It has long been known that with the use of 
NDMR drugs comes the potential for residual neuromuscular 
blockade after the end of anaesthesia and subsequently an 
increase in postoperative morbidity and mortality. Clinical 
methods such as the five-second head lift are commonly used to 
ascertain muscle function at the end of surgery; however, these 
methods have been shown to be insensitive and inferior to 
quantitative methods, most notably quantitative TOF ratio 
measurement. Furthermore, decreased incidence of postoperative 
residual curarisation has been demonstrated in units that have 
applied routine use of quantitative TOF ratio measurement as part 
of their unit protocols when using non-depolarising muscle 
relaxants.30,32 Despite this evidence, however, many anaesthetists 
still do not routinely use methods other than clinical indicators to 
ascertain muscle function at the end of surgery.
A TOF ratio value of greater or equal to 0.9 is currently widely 
recommended as the minimum acceptable TOF ratio prior to 
extubation.5,10,20,27 TOF ratio cut-offs of 0.7 and 0.9 were used in this 
study to align with previously recommended minimum acceptable 
values and to allow for easy comparison between practices at the 
study centre and other centres where similar studies have been 
performed.18,24–26 A further cut-off of TOF ratio values less than 1.0 
was included after recent studies demonstrated a tendency for 
overestimation of the TOF ratio by acceleromyographic-based 
neuromuscular stimulators such as the TOF-Watch SX®.26, 28 The 
cut-off value of 1.0 was suggested to compensate for this tendency 
and ensure an effective TOF ratio of 0.9.
The incidence at the study centre of 28.6% of patients arriving in 
the PACU with a TOF ratio of less than 0.9, and 7.1% with a TOF 
ratio of less than 0.7 compared favourably with a recent meta-
analysis that published estimates of around 40% and 12% 
respectively.27 A similar South African study in 2004 of 70 subjects 
at Universitas Hospital in Bloemfontein demonstrated a higher 
incidence of residual neuromuscular block with 42.9% of their 
patients arriving in PACU with a TOF ratio of less than 0.9 and 
17.1% with a TOF ratio of less than 0.7.22 The reason for the 
variance is beyond the scope of this study but may reflect 
multiple potential factors such as marked increased use of newer 
non-depolarising muscle relaxants with an altered 
pharmacokinetic profile, such as rocuronium, since the earlier 
study was performed. Other potential factors include a difference 
in the spectrum of surgical procedures performed at the various 
centres, as well as varying levels of experience amongst the 
anaesthetic practitioners involved. When utilising the newly 
proposed cut-off value of less than 1.0, in order to ensure an 
effective clinical TOF ratio greater than 0.9, the percentage of 
subjects classified as having inadequate return of muscle 
function increases to a sizeable 62.9% of patients. It must be 
noted, however, that the use of this value as a cut-off is still not 
widely accepted and has yet to be verified in studies as having a 
direct clinical correlation.
Various studies have found conflicting results as to whether a 
significant difference can be found in TOF ratios when analysed 
according to age and gender.6,22,33,34 When reviewing the data 
according to demographics, there were no significant differences 
between TOF ratios when grouped according to age or sex, 
although comparison is made difficult by the small sample sizes 
involved.
The validity of comparisons between the types of muscle 
relaxants and TOF ratios observed were also hampered by only a 
small sample of 6 (8.6%) patients in the study having received 
cisatracurium. The small sample recruited perhaps reflects a bias 
on behalf of the anaesthetic practitioners at the study centre 
towards the use of rocuronium, as choice of anaesthetic 
technique was left entirely to the practitioner’s discretion. A 
tendency for slightly improved muscle function after rocuronium 
was, however, observed when using a value of 0.9 as the cut-off 
(p = 0.051).
Neuromuscular blockade was reversed by the administration of 
neostigmine in the majority of patients in the study (95.7%), with 
all but three of the patients having received the drug. 
Interestingly, however, this did not significantly reduce the 
prevalence of postoperative residual partial paralysis as is 
evidenced in the results. This provides further motivation for the 
routine use of quantitative neuromuscular monitoring when 
using non-depolarising muscle relaxants as administration of 
neostigmine reversal alone cannot be relied upon to ensure the 
absence of residual paralysis.
Residual neuromuscular blockade may be the result of many 
different factors alone or in combination. High doses of non-
Table 1: Patient characteristics
TOF ratio Total < 0.7 < 0.9 < 1.0
Number 70 5 (7.1%) 20 (28.6%) 44 (62.9%)
Age 46.76 ± 16.98 50.4 ± 12.62 49.85 ± 11.97 47.32 ± 15.73




















Figure 1: Percentage of subjects with residual paralysis.
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depolarising muscle relaxants, repeat doses or infusions, the use 
of long-acting agents, as well as reversal agent choice, dosing and 
timing of administration can all contribute to increasing the risk 
of residual neuromuscular blockade. Further factors such as 
interacting agents (including residual volatile anaesthetic drugs), 
hypoxia, hypercarbia, acidosis, liver or renal impairment, 
hypothermia and age and weight of the patient can all increase 
this risk even further.5,14 The purpose of this study was to reflect 
purely on the number of patients with impaired muscle function 
postoperatively after receiving non-depolarising muscle 
relaxants. In doing so it did not attempt to comment on the 
causes of any impaired muscle function, as these may be both 
complex and numerous, and are beyond the scope of the study. 
Furthermore, morbidity and mortality associated with 
postoperative residual curarisation occurs independent of the 
causative factor involved, and as such any residual impairment 
noted in the PACU post-extubation should be a cause for concern.
What is most notable after reviewing the results of this study is 
that still, after many years of various authors repeatedly 
emphasising the issue of residual curarisation, and numerous 
recommendations for the routine use of quantitative TOF ratio 
measurements when using non-depolarising muscle relaxants, a 
significant proportion of patients in the study unit are still 
arriving in the PACU with impaired muscle function.8,11,18,26,30,32
This indicates that a renewed emphasis needs to be placed on 
educating anaesthetic practitioners about the problem of 
postoperative residual curarisation, as well as ensuring the availability 
of quantitative neuromuscular monitors in all surgical hospitals with 
the ultimate aim of incorporating objective neuromuscular 
monitoring as part of routine evidence-based practice.
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